2022 Massachusetts General Laws
Part I - Administration of the Government
Title XXII - Corporations
Chapter 176b - Medical Service Corporations
Section 4pp - Coverage for Long-Term Antibiotic Therapy for Lyme Disease; Experimental Drugs
[ Text of section added by 2021, 29, Sec. 24 effective July 1, 2021 until July 1, 2022. See 2021, 29, Sec. 69. Repealed by 2021, 29, Sec. 25.]
Section 4PP. (a) For the purposes of this section, "long-term antibiotic therapy'' and "Lyme disease'' shall have the meaning ascribed to them in section 12DD of chapter 112.
(b) A subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide coverage for long-term antibiotic therapy for a patient with Lyme disease when determined to be medically necessary and ordered by a licensed physician after making a thorough evaluation of the patient's symptoms, diagnostic test results or response to treatment. An experimental drug shall be covered as a long-term antibiotic therapy if it is approved for an indication by the United States Food and Drug Administration; provided, however, that a drug, including an experimental drug, shall be covered for an off-label use in the treatment of Lyme disease if the drug has been approved by the United States Food and Drug Administration.